NVCT Nuvectis Pharma, Inc Earnings per share for the last twelve months

NVCT (Nuvectis Pharma Inc.) - company brandmark

The EPS TTM history demonstrates profitability dynamics, where the current status is -1.86. Nuvectis Pharma, Inc. (NVCT) develops targeted therapies in collaboration with scientific centers. The business model relies on the full outsourcing of production and trials through external contractors. High demand for anti-tumor solutions provides the company with stability regardless of global economic shocks.

NVCT (Nuvectis Pharma, Inc.) Net earnings per share for the last 12 months history from 07/04/2022 to 11/16/2026

Nuvectis Pharma, Inc - analytical breakdowns and key metrics (NVCT)

- current quotes and average value forecast:
Basic company analysis:nuvectis.com (NVCT)
Mass-produced product of Nuvectis

TTM net income per share measures the final return of a single security over a year, excluding the impact of share issuances or buybacks to identify the real profitability trend. An analysis of TTM fundamental earnings per share allows for an assessment of the financial stability of Nuvectis Pharma, Inc. (NVCT), whose current results depend on investment income until the commercialization of oncology therapy drugs.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Heron Therapeutics Inc HRTX|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months